U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Press/Media: Press / Media

PeriodFeb 5 2016

Media coverage

17

Media coverage

  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletCNBC
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBloomberg
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletReuters
    CountryUnited Kingdom
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBusiness Wire
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletWall Street Select
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletYahoo! Finance
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletMoneyShow.com
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletPettinga Financial Advisors
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletEON: Enhanced Online News
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBioSpace
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletYahoo! Finance UK and Ireland
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletYahoo! Singapore
    CountrySingapore
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletFreshnews.com
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletPipelineReview
    CountrySpain
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletStock Nod
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBristol-Myers Squibb
    CountryUnited States
    Date2/5/16
    PersonsFred Poordad
  • TitleU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date2/5/16
    PersonsFred Poordad